Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Particip
More options for Her2 brain mets:
ClinicalTrials.gov Identifier: NCT01921335 Purpose The purpose of this study is to test the safety of different doses of ARRY-380 in combination with trastuzumab. Trastuzumab is an FDA approved drug for the treatment of HER2 metastatic breast cancer. However, the combination of ARRY-380 and trastuzumab has not yet been tested. Both agents block the HER2 receptor, which is thought to be overactive in HER2-positive breast cancer. It is thought that ARRY-380 and trastuzumab might work together because they attach to different parts of the HER2 receptor and prevent it from functioning. Because HER2 positive breast cancer contains high levels of HER2 receptor, but normal cells in your body generally do not, the drugs may be able to "target" the cancer cells. In addition, in laboratory studies, ARRY-380 appears to have some penetration into the brain. http://www.clinicaltrials.gov/ct2/sh...astasis&rank=9 |
Re: Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Part
Yes, this is the trial Kiri's on, Liz. She is in the lower dose arm, 750mg once a day I believe.
|
Re: Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Part
I checked the primary completion date: November 2016
There may be interim reports. I want to thank Kiri for enrolling in the trial. She is the pioneer that will help to determine effective doses and side effects. This trial sounds very promising for CNS mets. She is in our hearts and prayers for an outstanding result. Primary Outcome Measures:
Secondary Outcome Measures:
Estimated Enrollment: 50 Study Start Date: August 2013 Estimated Study Completion Date: November 2019 Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure) |
All times are GMT -7. The time now is 05:03 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021